Bio-Rad Laboratories, Inc.
BIO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $9 | $9 | $13 | $23 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $1 | $0 |
| Enterprise Value | $10 | $10 | $13 | $22 |
| Revenue | $3 | $3 | $3 | $3 |
| % Growth | -3.9% | -4.7% | -4.1% | – |
| Gross Profit | $1 | $1 | $2 | $2 |
| % Margin | 53.7% | 53.4% | 55.9% | 56.1% |
| EBITDA | -$2 | -$1 | -$4 | $6 |
| % Margin | -83.5% | -24.5% | -160.2% | 191.2% |
| Net Income | -$2 | -$1 | -$4 | $4 |
| % Margin | -71.9% | -23.9% | -129.5% | 145.6% |
| EPS Diluted | -65.36 | -21.82 | -121.79 | 140.83 |
| % Growth | -199.5% | 82.1% | -186.5% | – |
| Operating Cash Flow | $0 | $0 | $0 | $1 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $1 |